Coherex Wave Crest: New device for atrial appendage closure

Appendage closure devices have emerged as an alternative to anticoagulation in fibrillated patients with a contraindication for it. The study included 63 patients with paroxysmal, persistent or permanent FA coupled with a CHADS score >1 and eligible to interrupt anticoagulation. The primary endpoint was atrial appendage occlusion evaluated by ultrasound between 45 and 180 days after. After 45 days, 97% of patients had the right atrial appendage occluded and none had adverse events. 

Conclusion: This new device seems easy to use and safe, with a 97% success rate in the implant and 97% occlusion of the atrial appendage at 45 days.

Richard Heuser
2013-05-23

Original title: Left atrial appendage closure with the Coherex Wave Crest left atrial appendage closure device. 

More articles by this author

Coronary obstruction registry after TAVI

There is little information in the literature about the obstruction of the coronary ostia after percutaneous aortic valve implantation. 81 TAVI sites and programs...

Clinical results of TAVI in Asia

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia...

RIPCORD study: FFR changes clinical consideration of chest pain

The objective of this study was to evaluate whether routine use of FFR in all the coronary arteries could change the strategy in stable...

PATA – STEMI: thromboaspiration correlates with a lower index of microcirculatory resistance

Routine manual vacuum in patients with acute coronary syndrome and ST-segment elevation improves myocardial perfusion according to non-invasive parameters. Invasive assessment of microcirculation has...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...